Headlines about ABIOMED (NASDAQ:ABMD) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ABIOMED earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.2151442485318 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern’s analysis:
Several equities research analysts recently issued reports on the stock. BTIG Research reissued a “hold” rating on shares of ABIOMED in a report on Sunday, October 29th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price for the company in a report on Tuesday, November 7th. Jefferies Group increased their target price on shares of ABIOMED from $208.00 to $220.00 and gave the stock a “buy” rating in a report on Thursday, December 21st. Leerink Swann increased their target price on shares of ABIOMED from $200.00 to $265.00 and gave the stock an “outperform” rating in a report on Friday. Finally, BidaskClub lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $210.50.
ABIOMED (NASDAQ ABMD) traded down $0.11 during mid-day trading on Monday, reaching $228.18. The company’s stock had a trading volume of 245,040 shares, compared to its average volume of 258,396. ABIOMED has a 1-year low of $103.53 and a 1-year high of $229.43. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02. The company has a market cap of $10,090.00, a P/E ratio of 112.40, a price-to-earnings-growth ratio of 3.01 and a beta of 0.15.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The business had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. During the same period in the prior year, the company posted $0.20 EPS. The firm’s revenue for the quarter was up 28.9% compared to the same quarter last year. equities analysts predict that ABIOMED will post 2.41 EPS for the current fiscal year.
In other ABIOMED news, Director Dorothy E. Puhy sold 6,364 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $179.08, for a total value of $1,139,665.12. Following the completion of the transaction, the director now directly owns 39,532 shares in the company, valued at approximately $7,079,390.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $178.64, for a total value of $1,786,400.00. Following the completion of the transaction, the vice president now owns 56,757 shares of the company’s stock, valued at $10,139,070.48. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect ABIOMED (ABMD) Share Price” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/22/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-abiomed-abmd-share-price.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.